MCE 品牌
代理商厂商性质
杭州市所在地
注:本产品仅用于科研,不可用于临床
生物活性 | Bafilomycin A1 (BafA1) is a specific and reversible inhibitor of vacuolar H+-ATPase (V-ATPase) with IC50 values of 4-400 nmol/mg. Bafilomycin A1, a macrolide antibiotic, is also used as an autophagy inhibitor at the late stage. Bafilomycin A1 blocks autophagosome-lysosome fusion and inhibits acidification and protein degradation in lysosomes of cultured cells. Bafilomycin A1 induces apoptosis[1][2][3]. | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IC50 & Target |
| ||||||||||||||||
体外研究 (In Vitro) | Bafilomycin A1 is treated to different types of membrane ATPases with the I50 of 400 nmol/mg, 4 nmol/mg and 50 nmol/mg for the vacuolar ATPases of a fungus (N. crassa), a plant (Z. mays), and an animal (bovine abrenal medulla). The I50 values refer as μmol of Bafilomycin A1 per mg of protein giving 50% inhibition of ATPase activity[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||
体内研究 (In Vivo) | Chronic treatment with low-dose Bafilomycin A1 (0.1 mg/kg) slightly inhibits the tumor volume, but the final tumor volume does not differ significantly from the control. However, chronic treatment with high dose Bafilomycin A1 (1 mg/kg) inhibits the tumor growth significantly, compared with controls, after 21 days[8]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||
分子量 | 622.83 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C35H58O9 | ||||||||||||||||
CAS 号 | 88899-55-2 | ||||||||||||||||
中文名称 | 巴佛洛霉素A1;巴弗洛霉素A1 | ||||||||||||||||
结构分类 |
| ||||||||||||||||
来源 | Streptomyces griseus strains | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 | -80°C, protect from light | ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 100 mg/mL (160.56 mM; Need ultrasonic) H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|